In NSCLC, the combination of anti-PD-1 and dasatinib has been discovered to completely inhibit the proliferation and differentiation of tumor-infiltrating Treg cells, reduce Treg cell levels, induce tumor regression, and elicit immune memory [221]. This evidence concerns the gene PDCD1 and neoplasm.